Displaying drugs 6226 - 6250 of 6759 in total
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal muscle breakdown. C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is...
Investigational
Amonafide
Amonafide is a substance that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and intercalating agents.
Investigational
Ethanesulfonic acid
Experimental
Triethoxycaprylylsilane
Experimental
Birabresib
Birabresib is under investigation in clinical trial NCT02698176 (A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)).
Investigational
PLX51107
PLX51107 is a potent and selective inhibitor of the bromodomain and extraterminal (BET) protein family.[A257246,A257251] PLX51107 is under investigation in clinical trial NCT04022785 (PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome).
Investigational
TN-401
TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene.
Investigational
NFS-02
NFS-02 is a recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized gene (rAAV2-ND1).
Investigational
Timolumab
Timolumab is a recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1).
Investigational
VOR33
VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein.
Investigational
TN-201
TN-201 is a gene therapy comprising a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene.
Investigational
Trastuzumab duocarmazine
Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).
Investigational
Guadecitabine
Guadecitabine is under investigation for the treatment of Previously Treated Metastatic Colorectal Cancer.
Investigational
Denufosol
Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial. A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in...
Investigational
Thiosalicylic acid
Experimental
Amineptine
The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until 2005.
Illicit
Withdrawn
Displaying drugs 6226 - 6250 of 6759 in total